Filing Analysis
Regulation FD Disclosure
Filed Mar 31, 2026
LOW
Tvardi Therapeutics, Inc. announced its financial results and business highlights for the fiscal quarter and year ended December 31, 2025. The report was furnished under Item 2.02 and includes a press release as an exhibit.
Key Facts
- The filing was made on March 31, 2026, reporting on the period ended December 31, 2025.
- The company reported under Item 2.02 (Results of Operations and Financial Condition).
- The report includes Exhibit 99.1, which is the press release detailing financial performance.
- The filing was signed by CEO Imran Alibhai.
Other SEC Filing
Filed Mar 06, 2026
LOW
Tvardi Therapeutics, Inc. has scheduled its 2026 Annual Meeting of Stockholders for June 9, 2026. The filing outlines the specific deadlines for stockholders to submit proposals and director nominations for consideration at the meeting.
Key Facts
- The 2026 Annual Meeting of Stockholders is set for June 9, 2026.
- Stockholder proposals for inclusion in the proxy statement under Rule 14a-8 must be received by March 16, 2026.
- Advance notice for director nominations and other business under the Company's Bylaws must be received by March 16, 2026.
- Notice for director nominees under the SEC's universal proxy rule (Rule 14a-19) must be provided by April 10, 2026.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.